Holger Schmidt

Holger Schmidt

Berlin

Holger Schmidt is an advisor to executives in the health industry for Strategy&, PwC’s strategy consulting group. He is a Managing Director Strategy& Germany, based in Berlin. He is a member of the global Health practice, focuses on R&D and commercial strategy, and works with pharmaceutical, biotech, and medtech companies and providers. He also has cross-industry experience in telecommunications and consumer goods. His experience spans the E.U., U.S., and emerging markets, including Brazil, Russia, Korea, and Australia.

His areas of expertise include:

  • Product and portfolio strategies along the whole product lifecycle (e.g. R&D strategies, launch strategies, LCM strategies)
  • Business strategies (e.g. due diligences, growth strategies, corporate strategies)
  • Organisational strategies (e.g. business process design, organizational design, change)

Holger Schmidt’s client work has included:

Product and portfolio strategies

  • Brand strategy and launch program for a respiratory product
  • Launch planning for a cardiovascular product
  • Mature markets pricing strategy for a consumer brand
  • LCM strategy for a mature cardiovascular product
  • Portfolio strategy oncology

Business strategies

  • Corporate strategy for a biotech startup
  • Commercial due diligence of a major hospital chain
  • Go to market model development for a medtech startup
  • Business plan evaluation of a nuclear research facility
  • Business blueprint for a patient service program
  • Business concept for a healthcare focused real estate development at a major airport
  • Enabling growth for a pharmaceutical contract manufacturer
  • Healthcare strategy for a major testing, inspection, certification company

Organizational strategies

  • Set up of a global market access organisation for a pharma company
  • Development of a portfolio management process for major pharma company
  • Reorganisation of a pharma country organisation after sales decline
  • Set up of a global key account management for a pharma company
  • Optimisation of the go-to-market strategy and reorganisation of a country organisation of a major pharmaceutical company

A licensed physician, Holger Schmidt studied medicine at RWTH Aachen and Humboldt University Berlin and participated in exchange programs with Rijksuniversiteit Masstricht, Universidad de Barcelona and Tribhuvan University Kathmandu.

Published by Holger Schmidt